BIOMARX PHARMA
Company Snapshot
Company Overview
BiomaRx, founded as a spinout from Harvard University, is developing liquid biopsy-based diagnostics for cancer applications, with an emphasis on pancreatic cancer.
The initial product, called Bio Pan-Cancer, is for use on patients who are in high-risk groups for pancreatic cancer, including those with inheritable pancreatic cancer or with pancreatitis or diabetes. The Bio Pan-Cancer test uses a panel of biomarkers including both proteins and RNA, and the technology format is still being worked out. The key aspect of the test is this panel of biomarkers, which was shown to be able to differentiate pancreatic cancer and healthy pancreas tissue, and able to be used to detect the presence of pancreatic cancer as early as Stage 2.
In February 2017 BiomaRx began a collaborative effort with SHG Sciences and Woodland Biosciences. SBH Sciences provided 10 biomarker platforms and laboratory facilities; Woodland Biosciences provided expertise for studying metabolic disease and oncology.
Company's Business Segments
- Healthcare Solutions : The company develops, manufactures, and distributes advanced nutraceutical medicines that are formulated to support overall health and promote a balanced lifestyle.
Applications/End User Industries
- Healthcare
- Life Sciences